Dong-A ST announced on the 27th that its revenue for the third quarter of this year, based on standalone financial statements, reached 206.5 billion won, a 4.1% increase from the same period last year. This marked the second consecutive quarter in which quarterly revenue surpassed 200 billion won.
During the same period, operating profit recorded 21.4 billion won, a 27.7% increase from the same period last year, driven by efficient execution of selling and administrative expenses.
The growth in third-quarter revenue was attributed to the continued expansion of the ETC (prescription drugs) segment and increased sales in the digital healthcare segment.
The ETC segment recorded 155.9 billion won, a 7.3% increase from the same period last year. Key products such as Growth Hormone and Motilium maintained stable growth. The expansion of sales for introduced products, including Zycub, Deporelin, Tanamin, and Elidel Cream, also drove growth. The launch of the epilepsy treatment Excopy is scheduled for November, with additional revenue growth expected.
The overseas business segment recorded 39.2 billion won, a 3.9% decrease from the same period last year. Performance declined due to sluggish sales in the beverage segment, including BAC, but biopharmaceuticals continued their growth trend thanks to an expanded market share for daepoetin alfa in Japan.
The digital healthcare segment recorded 2.8 billion won, a 403% increase from the same period last year. Sales of HighCardi showed growth, while Doctor Eye and CareSense also contributed to revenue expansion. The impact of the second-half launch of 'HighCardi M350' is anticipated, and the company is expanding its digital healthcare business area by signing an exclusive sales contract for the AI gait analysis solution Neurogate.
In the Research and Development (R&D) segment, Vanoglipel (DA-1241), a treatment for MASH (metabolic dysfunction-associated steatohepatitis) and type 2 diabetes being developed through US affiliate Metavia, has completed its global Phase 2a clinical trial. The obesity treatment DA-1726 is currently undergoing Global Phase 1 Clinical Trial Part 3 to confirm safety upon reaching high doses and optimize tolerability based on a dose-escalation strategy. Phase 1 Part 3 extended the dosing period from the previous 16 weeks to 24 weeks. Key results for the 16th-week period are expected to be announced in Q4 of this year, while key results for the extended 24-week period are scheduled for release in Q1 next year.
A Dong-A ST official stated, "We have exceeded 200 billion won in revenue for the second consecutive quarter, based on stable growth in the ETC segment and the expansion of our digital healthcare business." The official added, "We will continue our growth trajectory with the goal of surpassing 800 billion won in annual revenue for the first time since our founding by strengthening the competitiveness of our core businesses and securing new growth drivers."
Meanwhile, Dong-A ST is a subsidiary of Dong-A Pharmaceutical. Dong-A Pharmaceutical and its related parties hold a 41.52% stake in Dong-A ST.
in THEBIO
